{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:10:46Z","timestamp":1788541846283,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"public, commercial, or not-for-profit sectors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: &lt;Brolucizumab&gt; AND &lt;AMD&gt; AND &lt;intraocular inflammation&gt;. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were 75.9 \u00b1 8.5 years, and 58.5% were female. IOI occurred 41.7 \u00b1 37.5 (median 37.0) days after treatment initiation with 2.0 \u00b1 1.3 (1\u20136) IVB injections. A mean change in visual acuity of \u221214.6 \u00b1 21.0 (median \u22126.5) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was 3.3 \u00b1 6.2 days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of \u221225.3 \u00b1 27.1 and \u22122.6 \u00b1 7.3 letters in the chronologically first and last third, respectively, of treated eyes (effect size: r = 0.71; p = 0.006). Functional outcomes markedly improved with increasing experience in managing IOI.<\/jats:p>","DOI":"10.3390\/jcm12144671","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T08:40:06Z","timestamp":1689324006000},"page":"4671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment\u2014A Meta-Analysis and Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"first","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Disease, Berner Augenklinik, 3007 Bern, Switzerland"},{"name":"Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Keiper","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Disease, Berner Augenklinik, 3007 Bern, Switzerland"},{"name":"Department of Ophthalmology, Inselspital (Bern University Hospital), University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-8390","authenticated-orcid":false,"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Disease, Berner Augenklinik, 3007 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-1103","authenticated-orcid":false,"given":"Christin","family":"Schild","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Disease, Berner Augenklinik, 3007 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/jamaophthalmol.2020.3989","article-title":"Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration","volume":"138","author":"Finger","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41433-020-0764-9","article-title":"Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration","volume":"34","author":"Chandra","year":"2020","journal-title":"Eye."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","article-title":"Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis","volume":"37","author":"Kim","year":"2017","journal-title":"Retina"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","article-title":"Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)\u2014A meta-analysis","volume":"259","author":"Garweg","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1007\/s12325-022-02248-5","article-title":"Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis","volume":"39","author":"Skelly","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gomi, F., Toyoda, R., Yoon, A.H., and Imai, K. (2021). Factors of Anti-Vascular Endothelial Growth Factor Therapy Withdrawal in Patients with Neovascular Age-Related Macular Degeneration: Implications for Improving Patient Adherence. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143106"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e14746","DOI":"10.1111\/dme.14746","article-title":"Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study","volume":"39","author":"Peto","year":"2022","journal-title":"Diabet Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00417-021-05187-z","article-title":"Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland","volume":"259","author":"Zirpel","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.mayocpiqo.2021.07.003","article-title":"Patients\u2019 Perspective About the Cost of Diabetes Management: An Analysis of Online Health Communities","volume":"5","author":"Gao","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","article-title":"Systematic review: Non-adherence and non-persistence in intravitreal treatment","volume":"258","author":"Ehlken","year":"2020","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Matonti, F., Korobelnik, J.F., Dot, C., Gualino, V., Soler, V., Mrejen, S., Delyfer, M.N., Baillif, S., Streho, M., and Gascon, P. (2022). Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071834"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","article-title":"Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: A systematic review and meta-analysis","volume":"37","author":"Rosenberg","year":"2023","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/jcm11020325","article-title":"Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression","volume":"11","author":"Veritti","year":"2022","journal-title":"J. Clin. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","article-title":"Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial","volume":"39","author":"Garweg","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000520171","article-title":"Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment","volume":"245","author":"Foss","year":"2022","journal-title":"Ophthalmologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00347-016-0306-9","article-title":"Atrophy of the macula in the context of its wet, age-related degeneration: An inescapable consequence of anti-VEGF therapy?","volume":"113","author":"Garweg","year":"2016","journal-title":"Ophthalmologe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524096","article-title":"Fluid control in neovascular age-related macular degeneration with brolucizumab: An analysis of the HAWK and HARRIER phase 3 trials","volume":"245","author":"Regillo","year":"2022","journal-title":"Ophthalmologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"860784","DOI":"10.3389\/fphar.2022.860784","article-title":"First Year Real Life Experience with Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration","volume":"13","author":"Abdin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00347-021-01474-6","article-title":"Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration","volume":"119","author":"Book","year":"2022","journal-title":"Ophthalmologe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"720345","DOI":"10.3389\/fphar.2021.720345","article-title":"Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice","volume":"12","author":"Montesel","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Haensli, C., Pfister, I.B., and Garweg, J.G. (2021). Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122666"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bilgic, A., Kodjikian, L., March de Ribot, F., Vasavada, V., Gonzalez-Cortes, J.H., Abukashabah, A., Sudhalkar, A., and Mathis, T. (2021). Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10132758"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2147\/OPTH.S395577","article-title":"Brolucizumab in Neovascular Age-Related Macular Degeneration-Indian Real-World Experience: The BRAILLE Study-Fifty-Two-Week Outcomes","volume":"16","author":"Chakraborty","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.2147\/OPTH.S376199","article-title":"Early Canadian Real-World Experience with Brolucizumab in Anti-Vascular Endothelial Growth Factor-Experienced Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Chart Review","volume":"16","author":"Giunta","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000526044","article-title":"Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes","volume":"245","author":"Hoshino","year":"2022","journal-title":"Ophthalmologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1038\/s41598-022-12216-2","article-title":"One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy","volume":"12","author":"Ito","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10384-022-00940-1","article-title":"Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration","volume":"66","author":"Kitajima","year":"2022","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1038\/s41598-022-10578-1","article-title":"One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 macular neovascularization","volume":"12","author":"Matsumoto","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00417-022-05793-5","article-title":"Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: An 18-month follow-up study","volume":"261","author":"Tanigichi","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/11206721221132619","article-title":"Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic","volume":"33","author":"Stepanov","year":"2023","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/aos.15242","article-title":"Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies","volume":"101","author":"Baumal","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_34","first-page":"4731","article-title":"Brolucizumab","volume":"15","author":"Murray","year":"2021","journal-title":"Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy. Clin. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","article-title":"Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER","volume":"6","author":"Singer","year":"2022","journal-title":"Ophthalmol. Retin."},{"key":"ref_36","first-page":"269","article-title":"Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J. Vitr. Dis."},{"key":"ref_37","first-page":"326","article-title":"Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis","volume":"5","author":"Witkin","year":"2021","journal-title":"J. Vitr. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER","volume":"128","author":"Srivastava","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/09273948.2021.1976220","article-title":"Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection","volume":"31","author":"Garweg","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.oftal.2022.02.006","article-title":"Guidance on brolucizumab management recommendations","volume":"97","author":"Fonollosa","year":"2022","journal-title":"Arch. Soc. Esp. Oftalmol. (Engl. Ed.)"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11845-022-02929-8","article-title":"Literature review and proposal of best practice for ophthalmologists: Monitoring of patients following intravitreal brolucizumab therapy","volume":"192","author":"Kilmartin","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1097\/IAE.0000000000003556","article-title":"A consensus on risk mitigation for broluzizumab in neovascular age-related macular degeneration: Patient Selection, Evaluation, and Treatment","volume":"42","author":"Holz","year":"2022","journal-title":"Retina"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40123-023-00647-7","article-title":"Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects","volume":"12","author":"Garweg","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ferrante, N., Ritrovato, D., Bitonti, R., and Furneri, G. (2022). Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-07972-w"},{"key":"ref_46","first-page":"743","article-title":"Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis","volume":"27","author":"Yu","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41433-021-01766-w","article-title":"An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma","volume":"36","author":"Ghanchi","year":"2022","journal-title":"Eye"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","article-title":"Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study","volume":"106","author":"Bulirsch","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration","volume":"139","author":"Baumal","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_51","unstructured":"Schmouder, R.L.M.B., Karle, A., Glick, J., Rubic-Schneider, T., Ledieu, D., Watts, J., and Brees, D. (, January 9\u201312). Immunologic features of Beovu\u00ae-associated retinal vasculitis\/retinal vascular occlusion. Proceedings of the EURETINA 2021 Virtual Congress, Virtual."},{"key":"ref_52","first-page":"2127","article-title":"Methodological quality of case series studies: An introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00347-020-01253-9","article-title":"Vaso-occlusive retinitis following intravitreal injection of brolucizumab","volume":"118","author":"Angerer","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Barchichat, I., Thiel, M., Job, O., and Schmid, M. (2022). Bilateral blindness after uneventful brolucizumab injection for macular degeneration. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02305-1"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fukuda, Y., Sakurada, Y., Matsubara, M., Hasebe, Y., Sugiyama, A., Kikushima, W., and Kashiwagi, K. (2021). Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy. Biomedicines., 9.","DOI":"10.3390\/biomedicines9091164"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10384-021-00819-7","article-title":"Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic","volume":"65","author":"Hikichi","year":"2021","journal-title":"Jpn. J. Ophthalmoll."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.oret.2021.08.010","article-title":"Early Recovery from Vasculitis after Brolucizumab with Prompt Steroid Treatment","volume":"6","author":"Iesato","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100989","DOI":"10.1016\/j.ajoc.2020.100989","article-title":"Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study","volume":"20","author":"Iyer","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","article-title":"Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy","volume":"65","author":"Kataoka","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00347-021-01343-2","article-title":"Acute unilateral loss of vision after intravitreal injection of a VEGF inhibitor","volume":"118","author":"Kaupke","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00347-021-01330-7","article-title":"Bilateral vasculitis following intravitreal brolucizumab injection","volume":"119","author":"Kessler","year":"2022","journal-title":"Ophthalmologe"},{"key":"ref_64","first-page":"196","article-title":"Bilateral Vasculitis after Single Intravitreal Brolucizumab Injection","volume":"239","author":"Kessler","year":"2022","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","article-title":"Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity","volume":"138","author":"Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.ajoc.2022.101521","article-title":"Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation","volume":"26","author":"Kusuhara","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00347-021-01341-4","article-title":"Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab","volume":"119","author":"Leclaire","year":"2022","journal-title":"Ophthalmologe"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Lee, E.K., Oh, B.L., Yoon, C.K., and Park, U.C. (2022). Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: A case report. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02465-0"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/ijo.IJO_3436_20","article-title":"Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy","volume":"69","author":"Narayanan","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1177\/11206721211059332","article-title":"Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center","volume":"32","author":"Nguyen","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00347-021-01323-6","article-title":"Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration","volume":"119","author":"Riedel","year":"2022","journal-title":"Ophthalmologe"},{"key":"ref_72","first-page":"2659714","article-title":"Early OCT Angiography Changes of Macular Neovascularization in Patients with Exudative AMD Treated with Brolucizumab in a Real-World Setting","volume":"2022","author":"Rau","year":"2022","journal-title":"J. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101727","DOI":"10.1016\/j.ajoc.2022.101727","article-title":"A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer","volume":"28","author":"Saito","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e27580","DOI":"10.1097\/MD.0000000000027580","article-title":"The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation","volume":"100","author":"Shigemoto","year":"2021","journal-title":"Medicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1159\/000518809","article-title":"Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolucizumab-Related Intraocular Inflammation","volume":"12","author":"Yoshikawa","year":"2021","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_76","first-page":"2561","article-title":"Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab","volume":"260","author":"Boltz","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4103\/IJO.IJO_2688_22","article-title":"Incidence, clinical features, risk factors, and outcomes of intraocular inflammation following brolucizumab in Indian eyes \u2013A multicentric study","volume":"71","author":"Chakraborty","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/IAE.0000000000003582","article-title":"Risk of intraocular inflammation after injection of antivascular endothelial growth factor agents: A Meta-analysis","volume":"42","author":"Patil","year":"2022","journal-title":"Retina"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","article-title":"Retinal Vasculitis or Vascular Occlusion after Brolucizumab for Neovascular Age-Related Macular Degeneration: A Systematic Review of Real-World Evidence","volume":"43","author":"Wykoff","year":"2023","journal-title":"Retina"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40123-022-00617-5","article-title":"Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and\/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab","volume":"12","author":"Igwe","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Mukai, R., Matsumoto, H., and Akiyama, H. (2021). Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259879"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.ajoc.2022.101788","article-title":"Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema","volume":"29","author":"Hirano","year":"2023","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results from Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/14\/4671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:45Z","timestamp":1760127105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/14\/4671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":84,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12144671"],"URL":"https:\/\/doi.org\/10.3390\/jcm12144671","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}